Disfunción sexual femenina: opciones de tratamiento farmacológico

Shifren, 2008, Sexual problems and distress in United States women: Prevalence and correlates, Obstet Gynecol., 112, 970, 10.1097/AOG.0b013e3181898cdb Kingsberg, 2015, Female sexual dysfunction: Focus on low desire, Obstet Gynecol., 125, 477, 10.1097/AOG.0000000000000620 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [Internet] [consultado 15 Dic 2015]. Disponible en: http://dx.doi.org/10.1176/appi.books.9780890425596 Buster, 2013, Managing female sexual dysfunction, Fertil Steril., 100, 905, 10.1016/j.fertnstert.2013.08.026 Association of Reproductive Health Professionals. Women's sexual health in midlife and beyond. ARHP Clin Proc.2005;5:8-12 [Internet] [consultado 15 Dic 2015]. Disponible en: http://melaniedavisphd.com/wp-content/uploads/2009/04/monson-womens-sexual-health-midlife-and-beyond.pdf Conaglen, 2013, Drug-induced sexual dysfunction in men and women, Aust Prescr, 36, 42, 10.18773/austprescr.2013.021 1992, Drugs that cause sexual dysfunction: An update, Med Lett Drugs Ther., 34, 73 Wright, 2015, Female sexual dysfunction, Med Clin North Am., 99, 607, 10.1016/j.mcna.2015.01.011 Taylor, 2013, Strategies for managing sexual dysfunction induced by antidepressant medication, Cochrane Database Syst Rev, 5, CD003382 FDA approves first treatment for sexual desire disorder. FDA News Release. August 18, 2015 [consultado 15 Dic 2015]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm Stahl, 2015, Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, CNS Spectr., 20, 1, 10.1017/S1092852914000832 Alcántara Montero A, Brenes Bermúdez FJ. What you need to know about «female viagra». Semergen. 2015. doi: 10.1016/j.semerg.2015.08.007 [consultado 6 Feb 2016]. Disponible en: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=0&pident_usuario=0&pcontactid=&pident_revista=40&ty=0&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=es&fichero=S1138-3593(15)00310-X.pdf&eop=1&early=si Wierman, 2014, Androgen therapy in women: A reappraisal: An Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 99, 3489, 10.1210/jc.2014-2260 Tkachenko, 2013, An open-label, single and multiple-application of intranasal testosterone gel (TBS-2) in healthy premenopausal female subjects at three dose levels, J Sex Med., 10, 165 Suckling, 2006, Local oestrogen for vaginal atrophy in postmenopausal women, Cochrane Database Syst Rev., 4, CD001500 2012, The 2012 hormone therapy position statement of: the North American Menopause Society, Menopause., 19, 257, 10.1097/gme.0b013e31824b970a Utian, 2014, Attitudes and approaches to vaginal atrophy in postmenopausal women: A focus group qualitative study, Climacteric., 17, 29, 10.3109/13697137.2013.850480 Goldstein, 2005, Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women, J Sex Med., 2, 154, 10.1111/j.1743-6109.2005.00131.x Nappi, 2015, Advances in pharmacotherapy for treating female sexual dysfunction, Expert Opin Pharmacother., 16, 875, 10.1517/14656566.2015.1020791 Portman, 2013, Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy, Menopause., 20, 623, 10.1097/gme.0b013e318279ba64 Lodise NM. Chapter 8. Vaginal and vulvovaginal disorders. Handbook of nonprescription drugs. 17th ed. Washington, D. C.: American Pharmacists Association; 2012. Goldstein, 2013, Phase 3 clinical trial results with Femprox® treatment in FSAD patients show correlation of arousal with both lubrication and orgasm but not with desire, J Sex Med., 10, 58 Caruso, 2004, Placebo-controlled study of efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder, Urology., 63, 955, 10.1016/j.urology.2003.12.018 Portman, 2014, Bremelanotide for hypoactive sexual desire disorder: Analyses from a phase 2B dose-ranging study, Obstet Gynecol., 123, 131S Segraves, 2004, Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women, J Clin Psychopharmacol., 24, 339, 10.1097/01.jcp.0000125686.20338.c1 Safarinejad, 2010, A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women, BJU Int., 106, 832, 10.1111/j.1464-410X.2010.09208.x Carroll, 2014, Bupropion and bupropion analogs as treatments for CNS disorders, Adv Pharmacol., 69, 177, 10.1016/B978-0-12-420118-7.00005-6 Panjari, 2010, DHEA for postmenopausal women: A review of the evidence, Maturitas., 66, 172, 10.1016/j.maturitas.2009.12.017 Labrie, 2009, Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause., 16, 923, 10.1097/gme.0b013e31819e85c6 Chivers, 2010, Phosphodiesterase type 5 inhibitors and female sexual response: Faulty protocols or paradigms?, J Sex Med., 7, 858, 10.1111/j.1743-6109.2009.01599.x